User profiles for Khashayar Esfahani

Khashayar Esfahani

McGill University
Verified email at mcgill.ca
Cited by 1887

Moving towards personalized treatments of immune-related adverse events

K Esfahani, A Elkrief, C Calabrese, R Lapointe… - Nature reviews Clinical …, 2020 - nature.com
The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

…, S Ernst, D Logan, K Belanger, K Esfahani… - Nature medicine, 2023 - nature.com
Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance
to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of …

[HTML][HTML] Adverse events associated with immune checkpoint inhibitor treatment for cancer

K Esfahani, N Meti, WH Miller, M Hudson - Cmaj, 2019 - Can Med Assoc
We searched PubMed from 2010 to 2018 for articles about immunerelated adverse events
and immune checkpoint inhibitors and selected randomized controlled trials, systematic …

[HTML][HTML] Alemtuzumab for immune-related myocarditis due to PD-1 therapy

K Esfahani, N Buhlaiga, P Thébault… - … England Journal of …, 2019 - Mass Medical Soc
Alemtuzumab for Immune-Related Myocarditis Myocarditis after the use of immune checkpoint
inhibitors is a potentially fatal complication. Immune suppression with glucocorticoids is …

[HTML][HTML] The role of immune checkpoint inhibitors in classical Hodgkin lymphoma

N Meti, K Esfahani, NA Johnson - Cancers, 2018 - mdpi.com
Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young
patient population that it primarily affects. Although cure rates are high, survivorship can be …

[HTML][HTML] Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade

K Esfahani, WH Miller Jr - New England Journal of Medicine, 2017 - Mass Medical Soc
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade |
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube …

[HTML][HTML] Tofacitinib for refractory immune-related colitis from PD-1 therapy

K Esfahani, M Hudson, G Batist - New England Journal of …, 2020 - Mass Medical Soc
Tofacitinib for Autoimmune Colitis from Anti-PD1 Tofacitinib is a JAK inhibitor that decreases
cytokine production. In a woman with autoimmune colitis from the administration of …

[HTML][HTML] Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

K Esfahani, TA Al-Aubodah, P Thebault… - Nature …, 2019 - nature.com
Immune checkpoint inhibitor (ICI) use remains a challenge in patients with solid organ allografts
as most would undergo rejection. In a melanoma patient in whom programmed-death 1 (…

HSP90 as a novel molecular target in non-small-cell lung cancer

K Esfahani, V Cohen - Lung Cancer: Targets and Therapy, 2016 - Taylor & Francis
Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA
alone. Over the past decade, the discovery of driver mutations has changed the landscape for …

[HTML][HTML] A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer

K Esfahani, JS Agulnik, V Cohen - Frontiers in Oncology, 2014 - frontiersin.org
The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has
led to a paradigm shift and the development of specific molecular treatments. Tumors …